At a glance
- Originator Eisai Co Ltd
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders